Nxera seeks buyer for schizophrenia program after Boehringer snub
Japan-based Nxera Pharma is seeking buyers for its Phase II schizophrenia program after Boehringer Ingelheim decided not to exercise a licensing option. Boehringer Ingelheim, which held exclusive rights to license the portfolio of GPR52 agonists for neurological disorders, did not provide further information to Nxera. The rights to the program will now pass into the…